Orion OYJ (OTCMKTS:ORINY) Sees Unusually-High Trading Volume – Should You Buy?

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) shares saw unusually-strong trading volume on Thursday . Approximately 330 shares changed hands during trading, an increase of 131% from the previous session’s volume of 143 shares.The stock last traded at $40.61 and had previously closed at $40.7475.

Analyst Ratings Changes

Separately, Danske downgraded shares of Orion OYJ from a “buy” rating to a “hold” rating in a report on Thursday, January 15th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Orion OYJ Price Performance

The business has a 50 day simple moving average of $37.53 and a 200-day simple moving average of $37.60. The company has a market capitalization of $11.21 billion, a P/E ratio of 19.47 and a beta of 0.04. The company has a quick ratio of 1.19, a current ratio of 1.99 and a debt-to-equity ratio of 0.13.

Orion OYJ (OTCMKTS:ORINY) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.08 earnings per share (EPS) for the quarter. The business had revenue of $809.41 million during the quarter. Orion OYJ had a return on equity of 51.23% and a net margin of 26.68%. Analysts predict that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.